Cigna Q4 2025 Earnings Analysis

**Beta Finch Podcast Script****ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest corporate results to help you understand what's moving the markets. I'm Alex, and I'm joined by my co-host Jordan. Today we're breaking down Cigna Group's fourth quarter 2025 earnings call - and folks, there's a lot to unpack here.Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely, Alex. And wow, what a call this was! Cigna just delivered some impressive numbers while simultaneously announcing a massive $7 billion settlement with the FTC. It's like they cleared two major hurdles in one earnings cycle.**ALEX:** Right? So let's start with the headline numbers. Cigna reported full-year adjusted revenue of $275 billion - that's 11% growth year-over-year. Adjusted earnings per share came in at $29.84, up 9%. For 2026, they're guiding to at least $30.25 per share. Jordan, those are some solid numbers in what CEO David Cordani called a "pivotal year."**JORDAN:** They really are, Alex. And what caught my attention is how they're managing this transformation while maintaining growth. The company is essentially reinventing their pharmacy benefits model - moving to what they call a "rebate-free" system - while still hitting their financial targets. That takes some serious execution capability.**ALEX:** Let's talk about that FTC settlement because it's huge. $7 billion in out-of-pocket cost relief over ten years for 100 million customers. Cordani was pretty emphatic that this positions them well for their new pharmacy model they announced back in 2025. It sounds like they saw this regulatory wave coming and built their strategy around it.**JORDAN:** Exactly. And here's what's fascinating - they're saying this settlement actually aligns perfectly with their new business model. Instead of fighting the regulatory tide, they're riding it. The new model eliminates rebates, increases transparency, and supposedly keeps similar margin profiles. During the Q&A, analyst Lisa Gill pressed them on this, and Cordani was confident that the margin profile will remain similar even with this massive shift.**ALEX:** That's a bold claim. They're basically saying they can completely transform how they do business while maintaining profitability. The specialty pharmacy business seems to be a big driver here - 14% revenue growth and they mentioned 13% growth in specialty scripts.**JORDAN:** The specialty business is really their growth engine. It's gone from about 25% of the company three years ago to 35% now. Brian Evanko, the COO, highlighted that this is a $400 billion addressable market growing at high single digits. They're particularly bullish on biosimilars - expecting over $100 billion in savings from biosimilar adoption by 2030.**ALEX:** Speaking of Evanko, he also mentioned some interesting tech innovations. They're rolling out AI-powered digital tools, including a provider matching tool and real-time cost tracking. Plus they launched something called "Clarity" - a new healthcare offering with transparent pricing that they claim can save clients up to 10% in medical costs.**JORDAN:** The Clarity product is intriguing because it represents this broader shift toward transparency that seems to be driving everything Cigna is doing right now. No referrals needed, simple co-pay structure, single digital platform. It feels like they're trying to simplify healthcare, which honestly, is desperately needed.**ALEX:** Now, let's talk about some challenges. The medical care ratio guidance for 2026 is 83.7% to 84.7%, which analyst Kevin Fischbeck questioned. CFO Ann Dennison explained they're being prudent about elevated cost trends, even with repricingThis episode includes AI-generated content.